Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii.
Trimetrexate, a lipid-soluble antifolate, has considerably greater activity in inhibiting the dihydrofolate reductase of Toxoplasma gondii than do the conventional antifolates pyrimethamine and trimethoprim. In an investigation of the effect of trimetrexate on T. gondii, in vitro and in vivo studies were undertaken with peritoneal macrophage cultures and acutely infected mice. Against T. gondii cultured in mouse peritoneal macrophages, 10(-7) M trimetrexate inhibited replication of the organism compared with 10(-6) M pyrimethamine and 10(-4) M trimethoprim. In acutely infected mice, trimetrexate alone prolonged survival and, when combined with sulfadiazine, allowed 93%-100% of mice to survive. These studies suggest that trimetrexate alone or combined with a sulfonamide may provide a safe and effective alternative to pyrimethamine plus sulfonamide for the treatment of T. gondii diseases.
D000818:Animals; D002478:Cells, Cultured; D004359:Drug Therapy, Combination; D005493:Folic Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D008264:Macrophages / Q000469:parasitology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010419:Pentamidine / Q000494:pharmacology; D011739:Pyrimethamine / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000494:pharmacology / Q000627:therapeutic use; D014122:Toxoplasma / Q000187:drug effects* / Q000254:growth & development; D014124:Toxoplasmosis, Animal / Q000188:drug therapy* / Q000469:parasitology; D014295:Trimethoprim / Q000494:pharmacology; D016597:Trimetrexate
D005493:Folic Acid Antagonists; D011799:Quinazolines; D013411:Sulfadiazine; D010419:Pentamidine; D014295:Trimethoprim; D016597:Trimetrexate; D011739:Pyrimethamine